DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Kilitch Drugs (India) Limited — Board Meeting Intimation

NSE 56 min ago·2 Nov 2026, 10:55 am

Kilitch Drugs (India)

Kilitch Drugs (India) Limited has announced that its board of directors will meet on November 6, 2026, to review and approve the company's unaudited financial results for the first half of the fiscal year ending September 2026.

This update is significant for investors as it provides the first glimpse into the company's operational performance and financial health for the ongoing period. The results will help gauge the company's growth trajectory and market position ahead of its full-year financial reporting.

Investors should watch for details regarding revenue growth, profit margins, and any commentary from the management on future business prospects. The outcome of this meeting will likely influence the stock's short-term price movement.